Artificial intelligence-powered pharmacovigilance: A review of machine and deep learning in clinical text-based adverse drug event detection for benchmark datasets.

Journal: Journal of biomedical informatics
Published Date:

Abstract

OBJECTIVE: The primary objective of this review is to investigate the effectiveness of machine learning and deep learning methodologies in the context of extracting adverse drug events (ADEs) from clinical benchmark datasets. We conduct an in-depth analysis, aiming to compare the merits and drawbacks of both machine learning and deep learning techniques, particularly within the framework of named-entity recognition (NER) and relation classification (RC) tasks related to ADE extraction. Additionally, our focus extends to the examination of specific features and their impact on the overall performance of these methodologies. In a broader perspective, our research extends to ADE extraction from various sources, including biomedical literature, social media data, and drug labels, removing the limitation to exclusively machine learning or deep learning methods.

Authors

  • Yiming Li
    Department of Cardiology, West China Hospital, Sichuan University, Chengdu 610041, China.
  • Wei Tao
    Center for Nanomedicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115.
  • Zehan Li
    McWilliams School of Biomedical Informatics, UTHealth Houston, Houston, TX, USA.
  • Zenan Sun
    McWilliams School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
  • Fang Li
    Department of General Surgery, Chongqing General Hospital, Chongqing, China.
  • Susan Fenton
    McWilliams School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
  • Hua Xu
    Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Cui Tao
    The University of Texas Health Science Center at Houston, USA.